Abstract Glioblastoma (GBM) is the most common brain cancer and is highly lethal in both adults and children. 2-methoxyestradiol (2ME2) is a microtubule inhibitor that potently inhibits HIF1a, GBM angiogenesis and tumor growth in preclinical models. In patients, 2ME2 exhibits low toxicity and promising but inconsistent efficacy. Given its preclinical potency and its tolerability in patients, we sought to determine whether 2ME2 therapy could be enhanced by addressing resistance via combination therapy, and with biomarkers to identify responsive glioma subgroups. We demonstrate that the PTEN-PI3K axis regulates HIF1a in glioma models. We utilized isogenic-pairs of glioma cell lines, deficient in PTEN or stably reconstituted with PTEN, to determine the role of PTEN in 2ME2 sensitivity in vitro and in vivo. Chou-Talalay synergy studies reveal significant synergy when a pan-PI3K inhibitor is combined with 2ME2. This synergistic activity was correlated with a synergistic suppression of HIF1a accumulation under hypoxic conditions in glioma models. In vivo, 2ME2 markedly inhibited tumor-induced angiogenesis and significantly reduced tumor growth only in a PTEN reconstituted GBM models in both subcutaneous and orthotopic intracranial mouse models. Collectively, these results: (1) suggest that PTEN status predicts sensitivity to 2ME2 and (2) justify exploration of 2ME2 combined with pan-PI3K inhibitors for the treatment of this intractable brain cancer.
Introduction
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with an average survival of just over one year [1, 2] . Even after aggressive treatment, which includes surgery and concurrent temozolomide and radiation, survival is only extended 2.5 months [2, 3] . As standard medical practice yields little survival benefit, greater attention is being paid to personalized treatment related to the expression of specific molecular markers [4] . Phosphatase and tensin homolog (PTEN)-dependent dysregulation of signaling occurs in 40 % of all GBM cases, and loss of heterozygosity (LOH) is found in 60-80 % of cases [3] . In addition, approximately 15 % of GBMs exhibit gain of function mutations of PI-3-kinase (PI3K; Class I a subunit; PIK3CA) [5, 6] . PTEN is a tumor suppressor gene involved in a number of signaling pathways, most importantly the PI3K/Akt pathway in which it serves as a phosphatase acting on PIP3, dephosphorylating PIP3 which is required for the downstream activation of PDK1 and plekstrin-homologydomain serine threonine kinase (Akt) [7] . Akt regulates a large number of downstream pathways controlling progression through the cell cycle, protein synthesis, survival, apoptosis and migration [8, 9] .
The role of PTEN in controlling tumor-induced angiogenesis is well-established in brain tumors [10] . Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis that is induced under hypoxic conditions by a multistage process in which the a subunit of hypoxiainducible factor-1(HIF1a) plays a key role [11] . HIF1a is rapidly degraded by the proteasome under normoxia [12, 13] . Under hypoxia, HIF1a is translocated to the nucleus where it heterodimerizes with HIF1b (and activates the transcription of more than 40 genes important for adaptation and survival under hypoxia [14] . The role of PTEN-PI3K signaling in the regulation of HIF1a has been implicated by several groups [15] [16] [17] , however its exact role remains controversial [18, 19] .
A landmark report suggested that 2-methoxyestradiol (2ME2), a natural metabolite of estradiol inhibits tumor growth and angiogenesis by dysregulating HIF [20] . This drug showed potent anti-GBM activity in preclinical models, and multiple studies highlight its potential as an anti-tumor agent [21] [22] [23] . 2ME2 has completed Phase I/II clinical trials for breast [24] , renal [25] prostate [26] and GBM tumors [27] . It is currently in Phase II trials for multiple myeloma [28] , and it is also in Phase II trials combined with Bevacizumab (Avastin) for carcinoid tumors [29] . So far, in patients, 2ME2 has demonstrated low toxicity with promising but mixed efficacy in several cancer types including GBM [30, 31] . The emergence of 2ME2 resistance in GBM is not understood and the mechanism of action remains unclear. While there may be any number of escape pathways leading to 2ME2 resistance, one possible candidate is loss or mutation of PTEN which maintains control over the important PI3K-Akt oncogenic pathway [32, 33] . Given the potency of 2ME2 in preclinical models, positive effects in some patients and its tolerability, we were motivated to determine whether 2ME2 for GBM treatment could potentially be significantly enhanced by (1) circumventing GBM resistance with combination therapy, and (2) the discovery of biomarkers which would identify 2ME2 responsive GBM substrata.
Herein, we report that the capacity of 2ME2 to inhibit GBM angiogenesis and tumor growth in vivo depends on PTEN status. Our in vitro data implicate PTEN and PI3K in the regulation of HIF1a accumulation in glioma cells. Moreover, PTEN expression correlates directly with GBM sensitivity to 2ME2. The pharmacologic inhibition of PI3K synergized with 2ME2 to suppress HIF1a accumulation and cell proliferation. In vivo PTEN status of implanted GBM cell lines influenced the anti-angiogenic and antitumor efficacy of 2ME2. These results support, (1) the use of PTEN status to identify 2ME2 responsive glial tumors, and (2) the potential utility of combining 2ME2 with PI3K inhibitors for GBM treatment. The data may further suggest that 2ME2 has greater activity in lower grade glial tumors (WHO grades I or II) where PTEN is rarely mutated and remains intact.
Materials and methods
Tissue culture, cells and reagents U87MG and U373MG glioma cell lines were obtained from ATCC. Both of these human GBM cell lines lack PTEN expression but differ in terms of p53 status. The U87MG cell line retains wild type p53 whereas p53 is mutated in the U373MG cell line [34] . TheLN229vIII cells containing wild type PTEN, mutated p53 were transduced with the vIII mutated EGFR [35] . Muristerone induced U87MG GBM cell lines and their mutants G129E and G129R has been previously described [10, 36] . Generation of GFAP V12 Ras PTEN fl/fl cre?, GFAP V12 Ras PTEN fl/wt cre? or GFAP V12 Ras PTEN fl/fl are described in Supplementary text S1. All lines were propagated in Dulbecco's modified Eagle's medium (Cellgro, Invitrogen). LY294002 and 2ME2 was purchased from Calbiochem. SF1126 is a vascular targeted pan-PI3K inhibitor developed by SignalRx pharmaceuticals [35] . Antibodies were purchased; Human HIF1a (Transduction Laboratories), total and phosphorylated Akt (Ser-473), phospho-ERK, ERK, PTEN and Caspase-3 (Cell Signaling Technologies).
Hypoxia and inhibitor studies Cells were cultured in 95 % O 2 and 5 % CO 2 at 37°C and then placed in a hypoxic chamber (Billups chamber) at 1 % O 2 , 5 % CO 2 , and 94.9 % nitrogen. Cells were pretreated with 25 lM 2ME2 alone, 25 lM LY294002, or both, followed by normoxia or hypoxia for 16 h.
Western blots
For HIF1a Western blots, nuclear extracts were prepared using a modified Dignam protocol [37] . Extracts were electrophoresed, transferred, and immunoblotted according to standard protocols.
Proliferation and apoptosis studies
For combined dose effect and synergism analyses, the isobologram method was used [38] . Experimental details are provided in Supplementary Materials (S1). U87MG-Null and U87MG-PTEN cells were treated with 2ME2 at 25 or 50 lM concentrations for 24, 48 and 72 h. Caspase 3 cleavage was determined using a caspase 3 specific antibody and western blot analysis.
Animal studies
Athymic female mice (CD-1 nu/nu, 20-25 g) were obtained from the NIH/NCI. All studies were approved by Emory University's Institutional Animal Care and Use Committee (IACUC). 5 9 10 6 cells were injected subcutaneously into the right flank and treatment initiated when all tumors reached 80-100 mm 3 . 2ME2 (200 mg/kg) or vehicle control was injected intraperitoneally (IP) once daily until sacrifice. Terminally, tumors were excised, sectioned, and stained for CD31 (Supplementary S1). Orthotopic xenograft studies were conducted by implanting glioblastoma cells in the right frontal lobe of mice as described in Supplementary S1 [10] . Figure 1a demonstrates that both the PTEN reconstituted U87MG-PTEN and U373MG-PTEN GBM lines expressed PTEN, while there was no PTEN expression in the parental U87MG-Null and U373MG-Null cells. The role of PTEN-PI3K pathway in HIF1a accumulation has been reported [15] [16] [17] but remains an area of intense debate in the literature [18, 19] . In order to confirm participation of PTEN in the regulation of HIF1a, we utilized the U87MG cell lines in which PTEN expression (or mutants of PTEN) was controlled by a muristerone responsive promoter [10] . We also utilized our glioma cell line derived from the GFAPV12-Ras 9 PTEN fl/fl transgenic mouse, engineered to delete one or both alleles of PTEN using a retroviral cre recombinase. PTEN blocked hypoxic accumulation of HIF1a in muristerone-induced U87PTEN and GFAPV12RasPTEN fl/fl cre? cell lines, especially under serum-free conditions (Fig. 1b,  c) , while there was mild suppression of HIF1a in 2 % serum. There was no PTEN or G129R mutant PTEN effect when cells were in 10 % FBS, while under serum free conditions the G129E PTEN mutant blocked accumulation of HIF1a to some extent (Fig. 1b) . The G129E mutant dephosphorylates acidic phosphopeptides (maintains protein phosphatase activity), but cannot dephosphorylate lipid substrate PtIns(3,4,5)P 3, while the G129R mutant lacks protein and lipid phosphatase activity. The results suggest that PTEN regulates HIF1a accumulation under hypoxic conditions in a protein phosphatase dependent manner. To further support a role for PTEN/PI3K in control of HIF1a in glioma models, we examined the effects of a pan-PI3K inhibitor, SF1126, on the accumulation of HIF1a under hypoxia. SF1126 inhibited the hypoxic accumulation of HIF1a in a dose dependent manner with complete suppression at 50 lM (Fig. 1d ).
Results

Effect of PTEN and pan-PI3K inhibitors on HIF1a accumulation in glioblastoma models
2ME2 induced AKT phosphorylation under hypoxia which was suppressed by the pan-PI3K inhibitor; LY294002 and 2ME2 demonstrate synergy in blocking HIF1a accumulation in GBM cell lines Previous reports clearly indicate that 2ME2 dysregulates HIF1a, leading to decreased angiogenesis and tumor growth [39, 40] . Figure 1 unambiguously demonstrates that the PTEN-PI3K pathway regulates HIF1a in glioma cell lines, and taken together with reports that 2ME2 inhibits HIF1a activity [39, 40] , led us to hypothesize that PTEN and/or PI3K signaling might synergistically interact with 2ME2 to control HIF1a and angiogenesis in malignant gliomas. The pan-PI3K inhibitor, LY294002 potently inhibited p-Akt independent of PTEN status, while it inhibited p-ERK levels only in U87MG-PTEN reconstituted cells (Fig. 2a) . In contrast, 2ME2 treatment of LN229vIII (PTEN intact, activated EGFR) cells under hypoxic conditions increased AKT activation as measured by p-AKT immunoblots. This effect was blocked by LY294002 (Fig. 2b) .
Next we explored the potential synergistic effect of these drugs on HIF1a accumulation. Figures 2c, d show that HIF1a accumulation was suppressed in isogenic U373MG and U87MG lines treated with 2ME2 alone or in combination with LY294002. In both U87MG and U87MG-PTEN cells the combined treatment with 2ME2 and LY294002 prevented the hypoxic accumulation of HIF to an equal extent. A comparison of the effects of separate vs. combined treatment with 2ME2 and/or LY294002 in U373MG vs. U373MG-PTEN cells reveals dramatic increase in effect of combined 2ME2/LY294002 in the U373MG-PTEN reconstituted glioma cells. Therefore we conclude that for the U373MG isogenic pair, intact p53 is not required for PTEN to augment the capacity of the 2ME2/LY294002 combination to suppress HIF. Consistent with the above results, 2ME2 alone or in combination with LY294002 potently inhibited HIF1a accumulation in LN229vIII cells (Fig. 2e) . These results suggest that 2ME2 can regulate HIF1a protein expression during hypoxia more effectively when PTEN is present or PI3K is inhibited.
Synergistic activity of PI3K inhibitors and 2ME2 on proliferation
Before examining the combined effect of 2ME2 and LY294002 on proliferation, we determined the effect of 2ME2 on U87MG-Null and U87MG-PTEN cell lines ( ). Considering that a shared function of PTEN and PI3K inhibitors is to suppressPIP3 and AKT, we evaluated combined 2ME2-LY294002 treatment in PTEN-intact LN229vIII GBM cells (wild type PTEN, mutated p53, activating vIII EGFR mutation). Cell proliferation data revealed 2ME2 and LY294002 synergism, as indicated by combination index (CI) values (Fig. 3) . The CI was calculated using the Chou-Talalay equation, which takes into account both the potency (Dm or IC 50, inhibitory concentration 50 %) and shape of the dose curve [41] . Synergism was detected for both a 1:1 ratio and a 2:1 ratio of 2ME2 versus LY294002 for all tested doses up to the maximum 5000 nM of each drug.
2ME2 induced apoptosis is not altered by PTEN status
Our next point of investigation was to determine if PTEN status influences 2ME2 mediated apoptosis induction.
Interestingly, 2ME2 induced apoptosis in both U87MG-Null as well as U87MG-PTEN cell lines as revealed by a very similar kinetic pattern of caspase 3 cleavage (Fig. S2) . These results suggest that apoptosis induced by 2ME2 in vitro occurred in a similar manner in PTEN positive and PTEN null GBM cells in vitro.
PTEN status influences the antitumor and antiangiogenic activity of 2ME2
In agreement with previous reports [42] , our results demonstrated increased rate of tumor growth in U373MG-Null cells implanted into nu/nu mice as compared to U87MG-PTEN cells ( Fig. 4a-c ; p \ 0.0002). 2ME2 showed significant tumor inhibition in mice implanted with PTENpositive LN229 vIII or PTEN-reconstituted U373-PTEN tumors (Fig. 4a-c) . 2ME2 had no significant antitumor activity against the U373MG-Null GBM cell line in vivo (p = 0.877). Previous reports from our laboratory and others highlight the anti-angiogenic properties of 2ME2, PTEN and PI3K inhibitors [10, 20, 35] , so we performed CD31 staining on all tumors. We found that 2ME2 clearly suppressed angiogenesis in U373MG-PTEN and LN229vIII (PTEN intact) tumors but not in U373MG-Null 8) , 25 lM pan-PI3K inhibitor LY294002 (lanes 3 and 7), these two compounds in combination (lanes 5 and 9) or no treatment (lanes 2 and 6), for 16 h at 37°C and were exposed to 1 % oxygen (lanes 2-9)
or 20 % oxygen (lane 1). b-actin was used as loading control. Both LY294002 and 2ME2 decreased hypoxic accumulation of HIF1a, and together they more potent than either alone. d Role of PTEN in 2ME2-mediated regulation of HIF1a accumulation was evaluated using U373MG-Null and U373MG-PTEN cells with mutated p53. Cells were treated with inhibitor in similar conditions as described for U87MG Null and PTEN cells. 2ME2 alone had a more pronounced effect on the PTEN-reconstituted cells than PTEN-null cells, and the combination of 2ME2 with LY294002 was more potent than either drug alone. e. LN229VIII cells were treated with 2ME2 (10 or 25 lM), LY294002 (5 or 25 lM) or in combination (5 or 12. (Fig. 4d, e) . Collectively, these data imply that both the anti-angiogenic and anti-tumor effects of 2ME2 are augmented by PTEN expression within the tumor compartment.
PTEN status determines survival with 2ME2 treatment in an orthotopic brain tumor model
To confirm that the effect of 2ME2 on tumor growth depends on PTEN status, we used a well-established orthotopic brain tumor model [10] . Median survival in mice with U373MG-Null GBM tumors was 56 days in the 2ME2 treated group versus 45 days in vehicle controls (p = 0.87); (Fig. 5a ). Median survival with U373MG-PTEN GBM tumors was 106 days in the 2ME2 treated group vs. 79 days in vehicle controls (p = 0.028; Fig. 5b . These data suggest that 2ME2 has greater activity against intracranial tumor growth when PTEN is present.
Discussion
In this report, we utilized isogenic sets of glioblastoma cell lines reconstituted with PTEN or mutants of PTEN to investigate the potential role of PTEN and PI3K signaling as it relates to in vitro and in vivo sensitivity to 2ME2. PTEN participates in the control of glioma angiogenesis, and it is reported that PTEN, PI3K and 2ME2 have antiangiogenic properties and regulate HIF1a [10, 21, 39] . PTEN is a key tumor suppressor and dysregulation of the PTEN-PI3K-Akt axis has been implicated in the expansion and therapeutic resistance of GBM and other cancers [32, 33] . Considering the frequency of PTEN and PI3K mutations in GBM, and that the utility of 2ME2 for GBM therapy is diminished by the emergence of resistance, our studies were designed to determine specifically (1) if PTEN status could potentially inform the stratification of GBM in terms of predicted response to 2ME2, and (2) whether blockade of PI3K signaling combined with 2ME2 treatment would enhance anti-GBM efficacy. To date, no reports have emerged to examine the relationship between 2ME2 sensitivity and PTEN status in malignant glioma pathogenesis and treatment. We found that 2ME2 inhibited both hypoxic accumulation of HIF1a and GBM cell proliferation in vitro, effects that were significantly potentiated by the addition of the pan-PI3K inhibitor, LY294002 or the presence of PTEN (Figs. 3, 4) . The role of the PTEN-PI3K pathway in stabilizing HIF1a is controversial [19] . Our present studies with muristerone induced U87MG and GFAPV12 Ras cell lines clearly demonstrate that PTEN blocks HIF1a accumulation in glioma cells (Fig. 1) . On the same note, work done by Zundel et al. [17] suggests that loss of PTEN mediates HIF1a mediated gene transcription. Moreover, consistent with a previous report [15] , our results also showed that treatment with PI3K inhibitors SF1126 or LY294002 suppressed HIF1a accumulation in glioma cell lines (Figs. 1,  3 ). Most importantly, treatment with 2ME2 and LY294002 displayed a synergistic effect in suppressing cell proliferation as well as to block HIF1a accumulation, a finding which has significant potential clinical relevance (Figs. 3,  4) .
The second potentially clinically relevant conclusion from this study is that PTEN status within the tumor compartment may serve as a biomarker for GBM sensitivity to treatment with 2ME2. Our results suggest that 2ME2 suppression of HIF1a stabilization, tumor growth and angiogenesis depends on PTEN status (Fig. 5, 6-8) . Interestingly, the effect of PTEN reconstitution on these phenotypes occurred in an isogenic pair of U373MG cell lines which are mutated in p53. Hence, these data suggest that a functional p53 axis is not required for PTEN to exert these effects on 2ME2 sensitivity in vitro and in vivo. A [43] demonstrated that patients with p53 mutations have augmented response to anti-angiogenic therapy with Avastin. A number of recent reports link p53 to the control of HIF1a and both PTEN and PI3K are known to regulate p53 via mdm2 phosphorylation, eliciting speculation that this key signaling axis (PTEN-HIF1a-p53) may be an important determinant of malignant glioma pathogenesis and therapeutics [44, 45] . Finally, it has been reported that the PTEN promoter is regulated by p53 adding additional complexity to the interpretation our model systems [46] . 2ME2 reduced microvascular density and tumor growth in mice implanted with U373MG-PTEN GBM tumors, and significantly extended survival of mice bearing orthotopic wild type PTEN-intact tumors. This suggests that the antitumor efficacy of 2ME2 on GBM relates to an antiangiogenic effect within the stromal compartment rather than solely a direct tumor cell cytotoxic effect. 2ME2 suppressed HIF1a, an inducer of angiogenesis, more potently in PTEN-intact cells. Previously, reports addressing 2ME2 effects on tubulin in both the tumor and endothelial cell compartments indicate that 2ME2 may disrupt tumor-endothelium crosstalk, suppressing angiogenesis [20] .
In aggregate, the data in this study suggest that 2ME2 may be more efficacious in patients whose GBM tumors express a wild type PTEN tumor suppressor protein. It has previously been reported that PTEN status is predictive of responsiveness to EGFR inhibitor therapy in GBM [47] Therefore, it is reasonable to suggest that PTEN genetic and protein analysis in a patients tumor may serve as predictive biomarkers of response to 2ME2 therapy. Moreover, our data highlight the potential clinical utility of investigating combined pharmacologic inhibition of PI3K isoforms with 2ME2 for GBM therapy. These data may further suggest that 2ME2 may have greater activity in lower grade glial tumor (WHO grades I or II) where PTEN is rarely mutated and remains intact.
